20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T72958 | BCR-ABL-IN-7 | Bcr-Abl | |
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research. | |||
T39732 | BCR-ABL-IN-3 | ||
BCR-ABL-IN-3 is a highly effective and irreversibly binding inhibitor of Bcr-Abl, displaying a remarkable potency with an IC50 value of ≤100 nM for Ba/F3 Bcr-Abl T3151. This compound exhibits significant anti-cancer acti... | |||
T10489 | BCR-ABL-IN-2 | Others | |
BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I). | |||
T10488 | BCR-ABL-IN-1 | Bcr-Abl | |
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia. | |||
T5177 | Asciminib | ABL001 | Bcr-Abl |
Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM). | |||
T21785 | AG957 | Bcr-Abl | |
Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors[1]. | |||
T3071 | Olverembatinib | GZD 824 | Bcr-Abl |
Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM). | |||
T8488 | GMB-475 | Bcr-Abl | |
GMB-475 is a BCR-ABL1 tyrosine kinase degrader based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL).resulting in ubiquitinati... | |||
T8882 | Vodobatinib | K-0706 | Bcr-Abl |
Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity. | |||
T17267 | XL228 | IGF-1R , Bcr-Abl , Src , Aurora Kinase | |
XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively). | |||
T2429 | Olverembatinib dimesylate | GZD824 Dimesylate,HQP1351 | Bcr-Abl |
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I). | |||
T0152 | Bosutinib | SKI-606 | Bcr-Abl , Src , Autophagy |
Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases. | |||
T3063 | PD173955 | PD-173955,PD 173955 | Apoptosis , Bcr-Abl , Src |
PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC. | |||
T6300 | Degrasyn | WP1130 | Apoptosis , JAK , Bcr-Abl , DUB , Autophagy |
Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without affecting 20S proteasome) and activator of transcri... | |||
T1803 | GNF-5 | GNF 5 | SARS-CoV , Bcr-Abl |
GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It is an analog of GNF-2 with improved pharmacokinetic properties. | |||
T11916 | Lyn-IN-1 | Bafetinib analog | Bcr-Abl , Src |
Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and Lyn | |||
T63332 | BCR-ABL-IN-5 | ||
BCR-ABL-IN-5 is a Bcr-Abl (Breakpoint cluster region-Abelson) kinase inhibitor that acts on Bcr-AblWT (IC50: 0.014 μM) and Bcr-AblT3151 (IC50: 0.45 μM) and exhibits some anti-proliferative effects on leukemic cells. effe... | |||
T82909 | BCR-ABL-IN-8 | Bcr-Abl | |
BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1]. | |||
T63450 | BCR-ABL-IN-6 | ||
BCR-ABL-IN-6 (9h) is an imatinib derivative and a selective inhibitor of Bcr-Abl kinase that acts on Bcr-AblWT (IC50: 4.6 nM) and Bcr-AblT3151 (IC50: 277 nM). BCR-ABL-IN-6 (9h) was able to be used in the study of chronic... | |||
T63932 | BCR-ABL-IN-4 | ||
BCR-ABL-IN-4 is a BCR-ABLL inhibitor that exhibits anticancer activity.BCR-ABL-IN-4 has an inhibitory effect on cancer cell growth and is able to act on K562 cells (IC50: 0.67 nM) and BCR-ABL T315I-transfected Ba/F3 cell... |